普洛藥業(000739.SZ)獲芬苯達唑《獸藥產品批准文號批件》
格隆匯1月9日丨普洛藥業(000739.SZ)公佈,近日,公司全資子公司浙江普洛康裕製藥有限公司獲得國家農業農村部簽發的《獸藥產品批准文號批件》。
芬苯達唑為苯並咪唑類驅蟲藥,對家禽胃腸道和呼吸道線蟲有良效,其不僅對胃腸道線蟲成蟲及幼蟲有高度驅蟲活性,而且對網尾線蟲、片形吸蟲和絛蟲有良好效果,還有極強的殺蟲卵作用。
芬苯達唑原料藥為公司合同研發製備項目,也已經完成了相關海外的註冊認證工作。本次國內註冊認證的通過,標誌着公司該獸藥產品在國內市場取得了銷售許可。該項目進一步增強了公司原料藥的CDMO業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.